Clinical trials: Depression Symptom
Sleep Deprivation, Sleep Hygiene
Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Sleep is not simply the absence of wakefulness. Sleep is an active procedure, normally happening every night, and is absolutely vital. Good sleep is essential for our well-being.
- Conditions
- Sleep Deprivation, Sleep Hygiene, Sleepiness, Sleep Driving
- Trial name
- BASEL (NCT06027047)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Raivotech
Depression, Pain
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side…
- Trial name
- NCT00036335
- Testing
- Duloxetine Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Depression
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression.
- Trial name
- NCT01128452
- Testing
- EVT 101
- Where
- 14 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
The study will assess safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine (AGO178) in patients with Major Depressive Disorder over a 52-week open-label phase.
- Trial name
- NCT01156415
- Testing
- AGO178
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 837 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Post Surgical Respiratory Failure, Respiratory Complication
Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)
Investigators will enroll 493 patients who will undergo non-cardiac surgery, receive supplemental oxygen via face mask or nasal cannula, and will be on continuous pulse oximetry monitor in the Post Anesthesia Care Unit (PACU).
- Conditions
- Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
- Trial name
- NCT07793981
- Testing
- Linshom Continuous Predictive Respiratory Monitoring
- Where
- 2 sites in United States
- Volunteers
- 394 people
- Sponsor
- Linshom Medical, Inc.
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale.
- Trial name
- LENA (NCT00361491)
- Testing
- SSR149415
- Where
- 7 sites in Argentina, Bulgaria and 5 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily.
- Trial name
- NCT00429260
- Testing
- Saredutant
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Sanofi
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Depression, Anxiety
Meru Health Program to Treat Depression in Primary Care
Meru Health Inc. seeks to further validate the Meru Health Program (MHP) as a single solution to screening, referral, and treatment in primary care as compared to treatment as usual using a Randomized Controlled Trial (RCT) study…
- Trial name
- NCT05615662
- Testing
- Meru Health Program, Treatment as Usual
- Where
- United States
- Sponsor
- Meru Health, Inc.
Major Depressive Disorder, Major Depressive Episode
SAINT for MDD in an Inpatient Setting Follow-on
Randomized, multi-site, sham-controlled, double-blinded study
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT06462820
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
- Trial name
- NCT05655507
- Testing
- Zuranolone
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biogen
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Depression
Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder
This study is a phase II, randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical trial and 150 subjects with depressive disorder will be enrolled.
- Trial name
- NCT07018245
- Testing
- TJ0113
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Depressive Disorder, Major
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD- 2 (NCT07775300)
- Testing
- Brenipatide
- Where
- 170 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Depression
Single Dose Study of BMS-820836
The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses
- Trial name
- NCT00964912
- Testing
- BMS-820836
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb